Omnicell, Inc.
29.57-0.37 (-1.24%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · OMCL · USD
Key Stats
Market Cap
1.36BP/E (TTM)
59.14Basic EPS (TTM)
0.50Dividend Yield
0%Recent Filings
8-K
Bylaws tightened for nominations
Omnicell amended its bylaws on September 30, 2025, tightening stockholder nomination and proposal rules with added disclosures from proposers and nominees. These changes align with Exchange Act requirements, including Rule 14a-19, while clarifying forum jurisdiction for lawsuits. The tweaks aim to streamline governance. No financial impact disclosed.
8-K
Omnicell names new CFO
Omnicell appointed Baird Radford as Executive Vice President and Chief Financial Officer effective August 26, 2025, succeeding Nchacha Etta, who steps down but advises through November 15. Radford, with over 30 years in healthcare and tech finance from roles at Allakos, HeartFlow, and Intuitive Surgical, starts at a $525,000 base salary plus up to $3.3 million in initial equity and a 90% target bonus. This bolsters financial strategy amid Omnicell's digital transformation to autonomous pharmacy solutions. Transition risks loom if key talent departs.
10-Q
Q2 FY2025 results
Omnicell posted solid Q2 results, with total revenues up 5% year-over-year to $290.6M, driven by 4% growth in product revenues to $163.2M and 6% in services to $127.4M; year-to-date, revenues rose 7% to $560.2M. Gross margin expanded to 44% from 41%, reflecting favorable product mix and lower materials costs, while operating income swung to a $8.1M profit from $3.2M, though YTD shows a $3.5M loss versus $18.6M last year. Diluted EPS improved to $0.12 from $0.08, reconciling to 46.99M shares, with no anti-dilution noted. Cash climbed to $399.0M, bolstered by $68.7M operating cash flow, while free cash flow (derived) of $37.0M trails last year's $82.8M; total debt stands at $341.8M in convertible notes maturing 2025 and 2029, with $350M revolver fully available. No major M&A or impairments surfaced. Yet competition in medication automation could squeeze margins if rivals undercut on pricing.
8-K
Omnicell Q2 beats, raises FY guidance
Omnicell reported Q2 2025 revenues of $291 million, up 5% from last year, fueled by connected devices and services, with non-GAAP EPS at $0.45 and EBITDA at $38 million—both topping prior guidance. The company raised full-year 2025 outlook to $1.130-$1.160 billion in revenues, $130-$145 million in non-GAAP EBITDA, and $1.40-$1.65 in non-GAAP EPS, signaling robust demand. Innovation shines through. Yet debt at $342 million tempers flexibility amid economic pressures.
8-K
CFO Separation Extended
Omnicell extended CFO Nchacha Etta's separation to November 15, 2025, via a June 5 agreement, allowing him to stay in the role until a successor arrives or transition to advisor. He gets $925,062 severance, 12 months COBRA coverage, $10,000 outplacement, and one year extra equity vesting, while reaffirming non-compete and non-solicit covenants. Smooth handover aids stability. Transition ensures continuity.
IPO
Website
Employees
Sector
Industry
CCLD
CareCloud, Inc.
3.02-0.02
CMHSF
COMPREHENSIVE HEALTHCARE SYS IN
0.39+0.00
MCK
McKesson Corporation
807.63+3.04
MNDR
Mobile-health Network Solutions
2.71-0.27
OMC
Omnicom Group Inc.
75.24-1.68
OMDA
Omada Health, Inc.
25.20-1.58
OMI
Owens & Minor, Inc.
5.22-0.06
OMQS
OMNIQ Corp.
0.14-0.04
ONMD
OneMedNet Corp
2.37+0.17
TDOC
Teladoc Health, Inc.
8.23-0.13